Guggenheim Maintains Buy on Nanobiotix, Raises Price Target to $26
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Michael Schmidt maintains Nanobiotix (NASDAQ:NBTX) with a Buy and raises the price target from $8 to $26.
Guggenheim analyst Michael Schmidt maintains Nanobiotix (NASDAQ:NBTX) with a Buy and raises the price target from $8 to $26.